Multinational pharma firms Novo Nordisk A/S, Sanofi and Eli Lilly and Company have been hit hard in China’s first volume-based tender program for insulin products, amid deep slashes in prices and tender volumes, according to a report published by Chinese brokerage firm CITIC Securities on 29 November.
On 26 November, the three companies, along with eight Chinese domestic insulin makers, participated in a tender program organized by...